A5056267838- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Phagocytosis and Immune Regulation
- Cytokine Signaling Pathways and Interactions
- Cancer-related Molecular Pathways
- Neuroblastoma Research and Treatments
- Microtubule and mitosis dynamics
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Cancer, Lipids, and Metabolism
- Lung Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Computational Drug Discovery Methods
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Angiogenesis and VEGF in Cancer
- Hematopoietic Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center
2016-2025
Medical College of Wisconsin
2021-2025
Institute of Population, Health and Development
2024
University of Southampton
2024
Liverpool John Moores University
2024
Biolog (United States)
2024
Ho Chi Minh City University of Education
2024
Flinders University
2023
Cho Ray Hospital
2022
Strong Memorial Hospital
2022
Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients non-small-cell lung cancer (NSCLC). was combined chemotherapy to determine if it could improve the outcome of NSCLC.TRIBUTE randomly assigned good performance status and previously untreated advanced (stage IIIB/IV) NSCLC erlotinib 150 mg/d or placebo up six cycles carboplatin paclitaxel, followed by maintenance monotherapy erlotinib. Random...
Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed validated a robust 76-gene EMT signature using gene expression profiles from four platforms non-small cell lung carcinoma (NSCLC) lines patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.We conducted an integrated expression, proteomic, drug response analysis tumors NSCLC. A was...
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non-small cell (NSCLC) patients were to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers analyzed fresh core needle biopsy...
Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) potent, reversible, highly selective and orally available HER-1/epidermal receptor tyrosine kinase inhibitor. Preclinical data in various xenograft models produced greater inhibition than with either agent alone. Additionally, both agents have demonstrated benefit patients...
Purpose We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial patients previously untreated for metastatic colorectal cancer (mCRC), changes during treatment plasma cytokines angiogenic factors (CAFs) as potential markers response therapeutic resistance. Patients Methods conducted II, two-institution FOLFIRI B. Each 14-day cycle consisted (5 mg/kg), irinotecan (180 mg/m 2 ), bolus FU (400 leucovorin ) followed by 46-hour...
<h3>Importance</h3> In recurrent human papilloma virus (HPV)–driven cancer, immune checkpoint blockade with anti–programmed cell death 1 (PD-1) antibodies produces tumor regression in only a minority of patients. Therapeutic HPV vaccines have produced strong responses to HPV-16, but vaccination alone has been ineffective for invasive cancer. <h3>Objective</h3> To determine whether the efficacy nivolumab, an anti–PD-1 antibody, is amplified through treatment ISA 101, synthetic long-peptide...
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation TKIs that overcome T790M-associated resistance available, noninvasive approaches detection will critical guide management.Experimental Design: part of a multi-institutional Stand-Up-To-Cancer collaboration, we performed an exploratory analysis 40 patients with tumors progressing on...
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver non-small cell lung cancer (NSCLC)1-3. Targeted therapies approved for patients with 'classical' a small number of other mutations4-6. However, effective have not been identified additional EGFR mutations. Furthermore, the frequency effects atypical on drug sensitivity unknown1,3,7-10. Here we characterize mutational landscape 16,715 EGFR-mutant NSCLC, establish structure-function...
IntroductionProgrammed death-ligand 1 (PD-L1) expression may vary in different disease sites and at time points of the course. We aimed to investigate PD-L1 heterogeneity its usefulness as a predictive value for immune checkpoint inhibitor (ICI) therapy patients with NSCLC.MethodsPD-L1 was analyzed 1398 NSCLC. The ICIs 398 metastatic NSCLC assessed.ResultsPD-L1 significantly associated biopsy (p = 0.004). Adrenal, liver, lymph node (LN) metastases had highest continuous variable 1% or 50%...
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) remains a clinical challenge. Especially challenging are cases in which emerges through EGFR-independent mechanisms, such as pathways that promote epithelial-to-mesenchymal transition (EMT). Through an integrated transcriptomic, proteomic, and drug screening approach, we identified activation the yes-associated protein (YAP) forkhead box M1 (FOXM1) axis driver EMT-associated EGFR TKI...
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated poziotinib (NCT03066206). The achieved its primary endpoint, confirmed objective response rates (ORRs) 32% and 31% by investigator blinded independent review, respectively, median progression-free survival 5.5 months. Using preclinical studies, silico modeling, molecular dynamics simulations, we found that sensitivity was highly dependent on the...
Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI limited anti-PD-1/PD-L1 typically display minimal benefit. Given that IL6 is associated worse outcomes in patients NSCLC, we investigate whether part...
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given known epigenetic regulation critical SCLC programs, we hypothesized that subtype-specific patterns DNA methylation could be detected tumor or blood from patients. Using genomic-wide reduced-representation bisulfite sequencing (RRBS) two cohorts totaling 179 patients...
Abstract While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), independent contribution quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study 394 NSCLC patients, utilize pre-treatment computed tomography (CT) 18 F-fluorodeoxyglucose positron emission (FDG-PET) establish a habitat imaging framework for assessing regional heterogeneity within individual...
The availability of an i.v. form busulfan (Bu) has prompted investigation administration schedules other than the 4-times-daily dosage commonly used with oral Bu. We have studied allogeneic stem cell transplantation (SCT) preparative regimen comprising fludarabine (FLU) 50 mg/m2 on days -6 to -2 plus Bu 3.2 mg/kg daily in a 3-hour infusion -5 -2. was given 70 patients aged 15 64 years (median, 41 years) hematologic malignancy. Thirty-six (51%) had high-risk malignancy, 28 (40%) unrelated or...
PURPOSE: Endostatin, a 20-kd fragment of collagen XVIII, is potent inhibitor angiogenesis. We evaluated recombinant human endostatin (rh-Endo) in phase I trial designed to assess safety, pharmacokinetics, and serum markers angiogenesis patients with solid tumors. PATIENTS AND METHODS: Twenty-six were enrolled onto dose-finding rh-Endo administered as an intravenous bolus over 20-minute period once daily. Three each treated at dose levels 15, 30, 60, 120, 180, 600 mg/m 2 /d, seven 300 /d....
Complete bioavailability of i.v. busulfan (Bu) provides dose assurance by reducing the interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with oral formulation. We hypothesized that Bu-SE, represented area under plasma concentration versus time curve (AUC), would correlate treatment outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML). Therefore, we analyzed risk death, incidence regimen-related...
Src family kinases (SFKs) promote cancer progression and are commonly expressed in non-small-cell lung (NSCLC), but the clinical effects of SFK inhibition NSCLC unknown. We conducted a phase II trial inhibitor dasatinib for advanced NSCLC. tested hypotheses that activation epidermal growth factor receptor (EGFR) or modulation serum cytokines may predict response to dasatinib.Patients received as first-line therapy. Response was measured by tumor size on computed tomography scans metabolic...